来那度胺在淋巴瘤治疗中的研究进展：第57届美国血液学会年会报道

Research progress of lenalidomide in the treatment of lymphoma： reports from the 57th American Society of Hematology annual meeting

来那度胺具有免疫调节、抗肿瘤、调节肿瘤微环境等多重作用。自美国食品与药品监督管理局（FDA）批准来那度胺可用于治疗套细胞淋巴瘤以来，近期研究表明，来那度胺单药或联合治疗在其他类型淋巴瘤中同样具有广阔的应用前景。现结合第57届美国血液学会（ASH）年会上的最新报道，对来那度胺在淋巴瘤治疗中的研究进展进行介绍。

Lenalidomide is an oral immunomodulator with multiple functions including immune regulation, anti-tumor, and regulation of tumor microenvironment. Since the United States Food and Drug Administration （FDA） approved lenalidomide for the treatment of mantle cell lymphoma, recent studies have indicated that lenalidomide monotherapy or lenalidomide combinations in other types of lymphoma also has broad prospects. The treatment progress of lenalidomide in lymphoma will be summarized in this paper based on the new reports in the 57th American Society of Hematology （ASH） annual meeting.